Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

4 results about "Protein link" patented technology

In nervous system: Neurotransmitters and neuromodulators …activation by receptor proteins of linking proteins, which move across the membrane, bind to channel proteins, and open the channels. Another system is the cyclic adenosine monophosphate (cAMP) system.

Mitochondrial optogenetics-based gene therapies and their methods of use

PCT designated stageWO2026112440A1Peptide/protein ingredientsMicroencapsulation basedInner mitochondrial membraneNucleic acid sequence
The present disclosure is directed to compositions comprising mitochondrial optogenetics-based gene therapies and their methods of use. In some embodiments, a composition described herein comprises an expression vector comprising a first nucleic acid sequence encoding a channelrhodopsin fusion protein and a second nucleic acid sequence encoding a luciferase protein. In some cases, the first nucleic acid sequence and the second nucleic acid sequence are operably linked to an expression control sequence. In some instances, the channelrhodopsin fusion protein comprises a channelrhodopsin protein linked to an inner mitochondrial membrane-mitochondrial localization signal (IMM-MLS). In some implementations, when the expression vector is expressed, the luciferase protein is localized to the cytosol. In some cases, the IMM-MLS comprises a leading sequence from a mitochondrial inner membrane protein selected from ABCB10, ABCB140, Cytochrome C, and renal outer medullary potassium channel (ROMK).
Owner:OHIO STATE INNOVATION FOUND

A material for detecting serum plasma antibodies to nicotinic acetylcholine receptors and methods of use thereof

This invention provides a material for detecting serum plasma anti-nicotinic acetylcholine receptor antibodies and its method of use. The material comprises HEK293T cells transfected with three recombinant expression plasmids: the first plasmid encodes a truncated AChR α subunit; the second plasmid is a polycistronic plasmid encoding a fusion protein composed of a truncated AChR β subunit, an AChR δ subunit, and rapsyn protein linked by a P2A peptide; and the third plasmid encodes a truncated AChR γ subunit or ε subunit. After co-transfection with PEI, the cells are cultured in fresh complete medium for 25-35 hours after 7-9 hours post-transfection, followed by fixation, blocking, and preservation. This invention, through a three-plasmid system and antigen truncation modification, reduces cytotoxicity while ensuring high expression of the functional pentamer, significantly improving detection sensitivity and reagent shelf life.
Owner:TAIZHEN (JIANGSU) MEDICAL TESTING LABORATORY CO LTD

Heterologous proteins with axonemal proteins

ActiveUS12673977B2HeterologousNucleic acid
Provided herein are compositions and methods for the production of heterologous proteins in a cell including axonemes. The cells include a nucleic acid encoding a fusion protein expressed in the axoneme. The fusion protein includes an axonemal protein linked to a heterologous protein, and the fusion protein provides axonemal function to the cell.
Owner:TEXAS A&M UNIVERSITY

Method and kit for elimination of rheumatoid factor interference in immunoassays

PCT designated stageWO2026133233A1Biological testingRheumatoid factor igmAmino acid
Method and kit for elimination of rheumatoid factor interference in immunoassays The invention relates to an in vitro method of reducing and / or eliminating unwanted detection of an IgG antibody in an immunoassay on a biological sample containing rheumatoid factor (RF), the method comprising contacting said biological sample with a RF interference-reducing protein comprising an amino acid sequence of SEQ ID NO. 1, 2 or 3, and capable of binding to the Fc domain of IgG antibodies. Also disclosed is an in vitro method for detecting antibodies specific to an antigen in a biological sample that belong to one or more immunoglobulin classes other than IgG, which makes use of the aforementioned RF interference-reducing protein. There are further described a kit for carrying out the method of the invention and the use in said method of a fusion protein comprising said RF interference-reducing protein linked to a fusion partner.
Owner:DIASORIN ITALIA SPA